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Therapeutic efﬁcacy in a hemophilia B model using a
biosynthetic mRNA liver depot system
F DeRosa1, B Guild1, S Karve1, L Smith1, K Love2, JR Dorkin2,3, KJ Kauffman2,4, J Zhang1, B Yahalom5, DG Anderson2,4,6,7
and MW Heartlein1
DNA-based gene therapy has considerable therapeutic potential, but the challenges associated with delivery continue to limit
progress. Messenger RNA (mRNA) has the potential to provide for transient production of therapeutic proteins, without the need
for nuclear delivery and without the risk of insertional mutagenesis. Here we describe the sustained delivery of therapeutic proteins
in vivo in both rodents and non-human primates via nanoparticle-formulated mRNA. Nanoparticles formulated with lipids and lipid-
like materials were developed for delivery of two separate mRNA transcripts encoding either human erythropoietin (hEPO) or factor
IX (hFIX) protein. Dose-dependent protein production was observed for each mRNA construct. Upon delivery of hEPO mRNA in
mice, serum EPO protein levels reached several orders of magnitude (4125 000-fold) over normal physiological values. Further, an
increase in hematocrit (Hct) was established, demonstrating that the exogenous mRNA-derived protein maintained normal activity.
The capacity of producing EPO in non-human primates via delivery of formulated mRNA was also demonstrated as elevated EPO
protein levels were observed over a 72-h time course. Exemplifying the possible broad utility of mRNA drugs, therapeutically
relevant amounts of human FIX (hFIX) protein were achieved upon a single intravenous dose of hFIX mRNA-loaded lipid
nanoparticles in mice. In addition, therapeutic value was established within a hemophilia B (FIX knockout (KO)) mouse model
by demonstrating a marked reduction in Hct loss following injury (incision) to FIX KO mice.
Gene Therapy (2016) 23, 699–707; doi:10.1038/gt.2016.46
INTRODUCTION
The application of nucleic acids for therapeutic use has been of
interest to the scientiﬁc community for decades.1 While viral
systems have shown great promise and recent success, challenges
associated with safety, manufacturing and potency continue to
persist.2 Non-viral systems have many potential advantages but
have proven challenging to translate.3 In general, this work has
predominantly focused on the use of plasmid DNA (gene
therapy),4–6 small interfering RNA (RNA interference),7–10 antisense
oligonucleotides, microRNA (translation repression)11–15 and
aptamers.16–18 Messenger RNA (mRNA) has garnered much less
attention during this time, perhaps due to the widespread
consideration of its transient nature, and only recently has been
publicized to have therapeutic value in the treatment of various
diseases.19–30
Systemic mRNA therapy (MRT) is a new approach to the delivery
of therapeutic proteins in vivo, using biosynthetic mRNA
transcripts as the source for therapeutic protein.20–23 Protein
production derived from such exogenous mRNA takes advantage
of the endogenous protein translational machinery within the
body along with all of the endogenous post-translational
modiﬁcations and processing machinery that are present
in human cells and tissues. Theoretically, this approach could
enable the treatment of many diseases, including those in which
protein-based therapeutics are unattainable, such as large,
transmembrane proteins; heavily processed, post-translationally
modiﬁed proteins; or proteins requiring cytoplasmic delivery. In
addition to this, MRT could provide ﬂexibility with respect to
delivery within the body. The speciﬁc site of delivery and
subsequent translation need not be within the target organ for
therapeutic treatment. Protein production derived from the
delivered mRNA can remain intracellular or can be secreted to
treat the respective disease systemically. Finally, MRT has potential
advantages over other nucleic acid protein replacement platforms
such as gene therapy, including the lack of requirement
for nuclear localization and elimination of insertional
mutagenesis risks.
As with almost all nucleic acid-based therapeutics, intracellular
delivery is required to achieve function. Over the years, many
different modalities have been examined, including viral
vectors,31,32 polymers,33–40 lipid nanoparticles (LNPs)41–43 and
covalent conjugation.44–47 Here we develop therapeutic LNPs,
using lipid and lipid-like materials for the delivery of mRNA to
hepatocytes. mRNA is notoriously labile, especially under biologi-
cal environments such as exposure to endo- and exonucleases
present within plasma.48 Encapsulation of RNA within LNPs can
provide for sustained RNA stability.49 In general, LNPs are
formulated with either a cationic or ionizable lipid or lipidoid,
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several helper lipids and a nucleic acid payload, which can
facilitate accumulation in speciﬁc sites within the body by
manipulation of size and/or inclusion of targeting agents.49–55
While considerable progress has been made in the clinical
development of small interfering RNA delivery systems, the
intravenous delivery of LNP-encapsulated mRNA in primates has
not been demonstrated.56–64
Here we describe the ﬁrst example of efﬁcacy in a human
disease mouse model using a lipidoid-based LNP formulation for
systemic delivery of mRNA, in vivo. A formulation containing the
cationic lipidoid C12-200 was developed for the delivery of
in vitro-synthesized mRNA. LNPs containing mRNA constructs for
either human erythropoietin (hEPO) or human factor IX (hFIX)
were developed. Delivery of the mRNA to hepatocytes was
conﬁrmed using in situ hybridization (ISH) methods. Robust
protein production from both exogenously synthesized mRNA
transcripts was observed and quantiﬁed in multiple species,
including non-human primates. Further, pharmacodynamic effects
were assessed and proof of efﬁcacy was established within
a hemophilia B (FIX knockout (KO)) disease model.65
RESULTS
We examined the potential of LNP-formulated mRNA for two
therapeutic proteins, hEPO and hFIX, as well as the utility of FIX
in a relevant disease model. Quantitative measurement
demonstrated that the desired proteins derived from exogenous
human mRNAs were delivered at supraphysiological levels via LNP
formulations. Protein secretion resulted in potent pharmacody-
namic effects as well as therapeutic efﬁcacy in a KO mouse model.
In vivo hEPO protein production
To evaluate the ability of mRNA-encapsulated lipidoid nanopar-
ticles to facilitate the delivery of mRNA, we monitored both hEPO
mRNA as well as hEPO protein levels in the serum over a 1-week
time period. This was performed as a single-dose administration
(1.0 mg kg− 1 based on encapsulated mRNA) given intravenously.
All formulations were well tolerated in the mice at the given dose
with no observable adverse events.
ISH methods were used to evaluate the delivery of hEPO mRNA
to the liver. As represented in Figure 1, a strong positive signal for
hEPO mRNA was detected from the earliest time point within the
experiment (30 min post administration). hEPO mRNA was
detected in both the sinusoidal cells as well as hepatocytes
within treated mouse livers with no cross-reactivity observed for
endogenous mouse EPO transcripts (Figure 1). mRNA was still
present at detectable levels within the hepatocytes up to 72 h
after a single dose.
As expected for a secreted protein, hEPO was detected in the
serum at various time points after administration of hEPO mRNA-
loaded C12-200 lipidoid nanoparticles (Figure 2). hEPO protein
30 min 3 hr 6h
12h 24h 48h
72h 1 week Untreated
Figure 1. Detection of exogenous hEPO mRNA via ISH. Positive staining was observed in hepatocytes as well as sinusoidal cells. Strong
detection was observed out to 72 h with remnant staining 1 week post administration.
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was present at markedly higher quantities than physiological
levels in a normal, healthy mouse at almost every time point
examined, yielding a maximum serum concentration at ~ 6 h post
administration. As shown in Figure 2 and listed in Table 1, upon
treatment with a 1.0-mg kg− 1 dose of EPO mRNA-encapsulated
LNPs, ~ 11 μg of hEPO protein per ml of serum can be produced.
This is several orders of magnitude (4125 000-fold) over the
normal human physiological level of EPO (average normal levels
reported to be 31.5–150 pg ml− 1, average ~ 90 pg ml− 1).66
Measurable levels of protein (~47 ng ml− 1, Table 1) were still
observed at 72 h with an appreciable increase over normal
physiological levels. This indicates that after 3 days, levels ~ 520-
fold over baseline physiological quantities were maintained.
Further, 1 week after a single dose of exogenous hEPO mRNA,
hEPO protein was present at slightly above normal physiological
levels (~120 pg ml− 1 serum). These data demonstrate the ability
of organs, which internalize LNP-delivered mRNA to act as a
‘depot’ for the production (and secretion) of hEPO protein.
This experiment also revealed the rapid onset of protein
production derived from such delivery. Approximately
190 ng ml− 1 of hEPO protein can be observed within 30 min of
dosing C12-200-based lipidoid nanoparticles delivering hEPO
mRNA. Therefore, an ~ 2000-fold increase over normal physiolo-
gical levels could be achieved in less than 1 h. Further, by 3 h,
levels of hEPO protein reached 4112 000-fold over normal.
To verify that the protein produced via mRNA-loaded lipidoid
nanoparticles was active, we measured hematocrit (Hct) levels in
mice following delivery of EPO mRNA. Hct changes were
monitored over a 15-day period as described above (Figure 3,
Table 2). Two separate dosing regimens were given to wild-type
mice: a single, bolus injection of 30 μg encapsulated hEPO mRNA
(~1.0 mg kg− 1) and three separate 10-μg injections on days 1, 3
and 5. As depicted in Figure 3, over the course of the study, both
dosing regimens produced a signiﬁcant increase in Hct (~20%
change), further demonstrating that hEPO protein produced from
a tissue depot is physiologically active using EPO mRNA
nanoparticles.
To further evaluate the potential of this formulation, we dosed
three male cynomolgus monkeys (~4 kg in body weight) and
monitored for hEPO protein production via serum analysis
over time (Figure 4). Each monkey received a single bolus,
intravenous injection via the ear vein of either hEPO mRNA LNPs
(two monkeys) or control LNP encapsulating nonsense mutated,
untranslatable mRNA (one monkey). The control formulation was
dosed at 0.025 mg kg− 1 while the two treated monkeys were
dosed at 0.025 and 0.050 mg kg− 1. All formulations were well
tolerated by the monkeys with no clinical signs and normal
physiological liver enzyme levels (alanine transaminase/aspartate
transaminase) observed (Supplementary Table 1).
While accounting for dose differences, the pharmacokinetic
proﬁle of EPO production in the cynomolgus monkeys shows
striking similarity to what was observed in mice (Figure 2; Table 1).
Serum EPO levels reach their maximum 6 h post administration,
while still detectable after 72 h at as low a dose of 0.025 mg kg− 1.
Monkeys treated with a dose of 0.050 mg kg− 1 demonstrated
hEPO protein levels of ~ 9000 pg ml− 1 (6 h time point), which
results in an increase over physiological levels by over 100-fold.
Figure 2. Quantiﬁcation of secreted hEPO protein levels as
measured via enzyme-linked immunosorbent assay (N= 4 mice per
group, error bars represent s.d.). The protein detected is a result of
its production from EPO mRNA delivered intravenously via a single
dose of LNPs (1.0 mg kg− 1 encapsulated hEPO mRNA) over time
(1 week). Aliquots of mouse serum were collected at the designated
time points.
Table 1. Concentrations of secreted human EPO protein over time as
measured via ELISA analysis (as depicted in Figure 1)
Time post administration (h) Secreted human EPO protein (ng ml− 1)
0.50 188
3 10 125
6 11 296
12 8521
24 6114
48 341
72 47.0
1 week 0.12
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EPO, erythro-
poietin. EPO mRNA (1.0 mg kg− 1) was delivered via C12-200-based lipidoid
nanoparticles. Values are depicted as ng of human EPO protein per ml
of serum.
Table 2. Hct levels of each group over a 15-day observation period
Formulation Dose (μg per
animal)
Hct levels, mean (%)± s.e.m.
Day − 4 Day 7 Day 10 Day 15
C12-200 30 50.8± 1.8 58.3± 3.3 62.8± 1.3 59.9± 3.3
C12-200 10 (×3) 52.2± 0.5 55.3± 2.3 63.3± 1.6 62.3± 1.9
Abbreviation: Hct, hematocrit. Mice were either dosed as a single, 30-μg
intravenous injection, or three 10-μg intravenous injections, every
other day.
Figure 3. Hct levels in mice (N= 4, error bars represent s.e.m.) treated
with either single intravenous dose of hEPO mRNA-loaded LNPs or
three injections (d1, d3 and d5). Whole-blood samples were taken
before injection (day − 4), day 7, day 10 and day 15.
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In sum, these data clearly demonstrate the ability to effectively
deliver mRNA to the liver when administering mRNA-loaded LNPs.
The exogenous mRNA was efﬁciently processed by the host
translational machinery to produce a fully formed, functional
protein. Further, this depot effect provides large quantities of
desired protein secreted systemically resulting in extended
pharmacokinetic plasma exposure proﬁles and substantial phar-
macodynamic effects within these mice.
In vivo hFIX protein production
To examine the potential of mRNA nanoparticles for the treatment
of hemophilia B, we formulated hFIX mRNA-loaded LNPs and
evaluated their activity in vivo. Successful delivery of hFIX mRNA
upon intravenous injection of a single 1.0 mg kg− 1 dose was
determined by ISH (Supplementary Figure 1). Staining patterns of
hFIX mRNA within both sinusoidal cells and hepatocytes were
equivalent to what was observed with EPO formulations (Figure 1).
Again, no cross-reactivity was observed for endogenous mouse
FIX transcripts within the liver. The strongest signal occurs at the
earliest time point analyzed (30 min) and diminishes over the
course of 3 days, with detectable mRNA still present at 72 h post
administration.
A pharmacokinetic analysis over 72 h showed that MRT-derived
FIX protein could be detected at all time points tested (Figure 5).
The peak plasma concentration was observed at 12 h post
injection with a value of ~ 4.4 μg of FIX protein per ml of plasma.
This robust protein production followed by secretion into the
blood stream for a sustained blood residence time represents
another successful example of the depot effect upon application
of LNP-mediated MRT.
To further establish the potential for MRT as a viable therapeutic
modality, we applied our hFIX mRNA-loaded LNPs in a hemophilia
B mouse model.65 FIX KO mice were treated with either saline or
C12-200-based hFIX mRNA-loaded LNPs (0.25 and 0.50 mg kg− 1).
FIX serum levels, activity and subsequent efﬁcacy were assessed in
this mouse model.
Plasma levels of hFIX protein were measured 12 and 24 h post
administration (Figure 6). Plasma FIX levels for a dose of 0.25 and
0.50 mg kg− 1 in the KO mice reached 400 ng ml− 1 and
1.77 μg ml− 1, respectively, 12 h post administration. All groups
were tested for FIX activity using a commercially available
chromogenic assay and are represented in Figure 7. The wild-
type (C57Bl/6) saline-treated group was normalized to represent
100% activity of FIX protein. The FIX KO saline-treated group
showed trace amounts of FIX activity (~1.15%) of wild-type levels.
This is consistent with, although slightly lower than, the 8%
residual activity reported previously as measured via an alternate
method.65 Upon treatment of the mice with hFIX mRNA, we
observed a marked increase in activity resulting in 40.9% and 87%
of wild-type levels for the 0.25 and 0.50 mg kg− 1 groups,
respectively.
Furthermore, given the high FIX levels observed, we expected
such doses to be therapeutic. We therefore hypothesized that
upon application of an incision wound, prolonged bleeding would
occur in the untreated KO mice as opposed to hFIX mRNA-treated
cohorts. These effects could be measured via changes in Hct levels
(that is, lower levels were a result of extended blood loss).
To achieve this, at ~ 12 h post administration, the mice were
subjected to a small surgical incision on the back of the animal.
This time point was selected to represent the maximum observed
hFIX protein plasma levels from the pharmacokinetic data
previously obtained in wild-type mice. As represented in
Figure 8, pre-treatment Hct levels averaged at ~ 47.7%. Final Hct
readings were taken from blood samples obtained 12 h post
incision (24 h post administration). Saline-treated FIX KO mice had
a ﬁnal Hct level of 17.9% representing a 62.5% overall decrease
from pre-treatment levels. Mice that were treated with hFIX mRNA
had much more sustained Hct levels measured at 36.1% and
Figure 4. hEPO protein levels observed over 72 h time course in
cynomolgus monkeys. Monkeys were either dosed at 0.025 or
0.050 mg kg− 1. Control formulation (untranslatable) was dosed at
0.025 mg kg− 1. Error bars represent replicates of analysis per
sample.
Figure 5. Quantiﬁcation of secreted hFIX protein levels measured
using enzyme-linked immunosorbent assay (N= 4 mice per group,
error bars represent s.d.). FIX protein is produced from FIX mRNA
delivered via nanoparticles (1.0 mg kg− 1 hFIX mRNA per single
intravenous dose, based on encapsulated mRNA). FIX protein is
monitored in plasma through 72 h.
Figure 6. Quantiﬁcation of secreted hFIX protein levels in FIX KO
mice (N= 5, error bars represent s.d.) after single, intravenous dose
(0.25 and 0.50 mg kg− 1, based on encapsulated mRNA). FIX protein
is measured in plasma 12 and 24 h post administration. Saline
represents control group.
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39.0% for 0.25 and 0.50 mg kg− 1 dosing, respectively. The overall
drop in Hct for the treated groups was signiﬁcantly inhibited
(24.3% and 18.2% overall decrease for 0.25 and 0.50 mg kg− 1,
respectively) as compared with the saline treatment, which can be
attributed to the presence of active FIX protein to restore clotting
and prevent further bleeding.
DISCUSSION
Here we describe the successful application of two separate
mRNA-loaded lipidoid nanoparticle systems toward hepatocyte
deposition of exogenous mRNA and subsequent high-level
protein production sustained over several days, creating a depot
system. Such a system is presumed to be the result of uptake and
clearance mechanisms with independent kinetic constants. These
include the kinetics of cellular uptake of the LNPs, the kinetics of
intracellular compartment escape (endosomal/lysosomal), the
kinetics of release of the exogenous mRNA, the half-life of the
mRNA, as well as the rate of translation of the mRNA into protein.
Further, with respect to secreted proteins, such processes may
occur in multiple organs to which the LNP was distributed,
resulting in contribution toward the total circulating pool of
protein produced from the exogenous mRNA. Previous studies
using this system (not reported) have demonstrated that480% of
the packaged mRNA is deposited in the liver. Moreover, an
additional complicating factor concerns possible differences in the
accessibility and function of the endogenous translational
machinery that could vary with different organs and is beyond
the scope of this work.
Observations of hepatocellular mRNA delivery and protein
production were consistent between the two mRNA constructs.
The ﬁrst mRNA transcript delivered using this approach was
designed to produce hEPO protein. EPO is a hormone, which has
long been used as a therapeutic with applications in anemia and
oncology.67 The majority of these drugs have been in the protein
form itself, serving as a hormone replacement/supplement
therapy. Recently, it has been demonstrated that naked, modiﬁed
EPO mRNA can be administered subdermally to mice with
favorable pharmacodynamic effects.20,21 We applied a synthetic
hEPO mRNA transcript toward LNP-based delivery for enrichment
in the liver. As demonstrated by ISH techniques, rapid deposition
in the liver was achieved, which was shown by intense staining in
both sinusoidal cells and hepatocytes within 30 min in the livers of
treated mice. Furthermore, detectable hEPO mRNA was observed
for up to 72 h after a single, intravenous administration.
High levels of protein production were observed following a
single treatment of hEPO MRT in wild-type mice as quantiﬁed and
depicted in Figure 2. Mouse serum levels reached 4125 000-fold
normal physiological levels of EPO protein (411.2 μg EPO per ml
of serum) within the ﬁrst 6 h of administration. As noted above,
rapid onset of protein production can be observed within 30 min
of administration while levels reached several orders of magnitude
above normal levels by 3 h post dose. Such observations indicate
the potential use of MRT as a protein production ‘depot’ therapy.
In the example presented here, a single 1.0 mg kg− 1 produces a
sustained exposure of hEPO protein that is detectable for 1 week
post administration.
Hct levels were monitored before and post treatment with EPO
MRT. Two dosing regimens were applied to wild-type mice
consisting of either a single, 30 μg bolus intravenous injection or
three 10 μg hEPO mRNA-loaded C12-200-based LNPs dosed every
other day (days 1, 3 and 5). Both dosing regimens resulted in an
~ 20% change in Hct as represented in Figure 3. These ﬁndings
conﬁrm that hormonal activity is maintained within the secreted,
MRT-derived hEPO protein upon encapsulation and delivery of the
respective mRNA via LNPs.
The potential of this formulation was further demonstrated by
the application of LNP-encapsulated hEPO mRNA in non-human
primates. A pharmacokinetic proﬁle of serum hEPO protein levels
was obtained in male cynomolgus monkeys when administered at
two separate doses (0.025 and 0.050 mg kg− 1, Figure 4) that was
remarkably similar to the results seen in mice. Serum levels of EPO
within both dose regimens could be detected up to 72 h post
administration within maximum levels reached by 6 h (matching
trends observed in mice vide supra). Control formulations
consisting of an untranslatable (nonsense mutated, non-protein
producing) mRNA construct resulted in no EPO protein detection
as anticipated. All formulations were well tolerated in all species
studied.
We used a second mRNA transcript (hFIX) using this LNP
delivery formulation to demonstrate the broad potential applic-
ability of the technology. The application of FIX MRT can be used
for the treatment of hemophilia B, a recessive, X-linked rare
genetic blood coagulation disorder predominantly caused by
mutations in the FIX gene.68–70 Patients suffering from this disease
have an inability to form proper blood clotting, resulting in
varying degrees of bleeding episodes as well as other complica-
tions. The only currently approved treatment modality for this
disease is the direct infusion of FIX enzyme, either from
recombinant or plasma-derived sources.68,69 Patients suffering
Figure 8. Hct levels of blood from FIX KO mice (N= 5, error bars
represent s.d.) 12 h post incision (24 h post injection). Mice were
either dosed with 0.25 or 0.50 mg kg− 1 of C12-200-based hFIX
mRNA-loaded LNPs. Control FIX KO mice were treated with saline.
Figure 7. FIX protein activity as measured by a chromogenic assay.
Controls include saline-treated wild-type (C57BL/6) and FIX KO
cohorts. All values are normalized to wild-type FIX activity values.
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from hemophilia B have been classiﬁed based on the percentage
of functional FIX protein within the body: 45–40% of normal
physiological levels is deﬁned as mild; 1–5% of normal physiolo-
gical levels is deﬁned as moderate; o1% of normal physiological
levels is deﬁned as severe.71 The relative ratio of each classiﬁcation
level within the patient population has not been fully determined,
however it has been reported that up to ~ 70% of patients suffer
from moderate to severe forms of the disease.72,73
hFIX mRNA was encapsulated in an identical fashion to that
described above using hEPO mRNA C12-200-based LNPs. Encap-
sulation efﬁciency as well as particle size was consistent with the
hEPO mRNA formulations. A pharmacokinetic study to assess
FIX protein production (and subsequent secretion) was performed
similarly to the EPO MRT study described above. Wild-type mice
were treated with a 1.0-mg kg− 1 single, intravenous dose of C12-
200-based hFIX mRNA-loaded LNPs, and were analyzed at
selected time points. To conﬁrm speciﬁc delivery and enrichment
of hepatic cells, ISH methods were used. Similar staining patterns
and amounts were observed when delivering hFIX mRNA via LNPs
as the previous EPO study (vide supra, Supplementary Figure 1).
Upon quantitative assessment of plasma hFIX protein levels within
the treated mice, we observed sustained protein production, with
subsequent secretion, for 72 h after a single, intravenous
administration. Again, high-level protein production resulted in
maximum plasma levels reaching ~ 4.40 μg of hFIX protein per ml
within 12 h of dosing (Figure 5). While normal physiological levels
of FIX protein are relatively high (2–3 μg ml− 1 plasma), the
observed FIX protein production in wild-type mice via FIX MRT can
be considered to be well within therapeutic levels.74 More
speciﬁcally, moderate to severe patients represent only up to
5% active protein available yet constitute up to ~ 70% of the
patient population.72,73 This equates to ~ 100 ng FIX protein per
ml plasma maximum. On the basis of a single 1.0-mg kg− 1 dose of
hFIX mRNA-loaded LNPs, we achieve ~ 40-fold higher than this
level. Therefore, a signiﬁcant portion of the patient population
may be candidates for a possible future treatment with this
modality.
To establish the possible therapeutic value of FIX MRT, we
applied this LNP technology toward a hemophilia B mouse
model.65 This model entails a FIX transgenic KO, which has been
reported to have minimal residual FIX activity. Traditional
measures of efﬁcacy in hemophilia models involve comparisons
of bleeding times or volumes upon tail snip.75,76 However, such
methods are sensitive to many variables, and protocols vary
considerably within the literature.77,78 We sought to establish an
alternative measure for efﬁcacy that would provide a surrogate for
FIX protein function. To this end, we measured Hct levels pre and
post incision to serve as a reﬂection of the degree of bleeding,
which occurred within treated and untreated animals.79 Mice
deﬁcient in FIX protein would demonstrate prolonged bleeding
episodes upon injury, which could be directly compared with
those mice, which have been pre-treated with FIX MRT.
FIX KO mice were treated with a single dose of FIX mRNA-
loaded C12-200 nanoparticles at either 0.25 or 0.50 mg kg− 1.
Plasma levels of hFIX protein were measured at 12 and 24 h post
administration (Figure 6). Plasma levels of FIX protein at 12 h
reached ~ 1.8 μg ml− 1 plasma and 400 ng ml− 1 plasma for 0.50
and 0.25 mg kg− 1 doses, respectively. These FIX concentrations
correspond to 90% (0.50 mg kg− 1) and 20% (0.25 mg kg− 1) of
normal physiological levels and are well within therapeutic range.
This is reﬂected both in the activity data and the Hct observations.
Detectable levels were still observed 24 h post administration at
724 and ~ 250 ng ml− 1 for the respective doses. Protein levels
observed in treated wild-type mice were equivalent for identical
doses (Supplementary Figure 2).
Further, FIX activity measurements were conducted on all
treated and untreated mice. Figure 7 represents a comparison
of activity of treated mice as compared with normal FIX activity
levels in untreated, wild-type mice (normalized to 100%). A single
0.50-mg kg− 1 dose of FIX MRT resulted in a restoration of activity
to 87% of wild-type levels. This level far surpasses the range of
‘mild’ deﬁned as 5–40% activity.71 Moreover, a single dose of only
0.25 mg kg− 1 provided activity of ~ 40% of wild-type levels. These
increases in activity levels are statistically signiﬁcant when
compared with the saline group, although one mouse demon-
strated abnormally high activity (105% of wild-type levels) in the
lower-dose cohort (0.25 mg kg− 1).
At 12 h post administration, a group of mice were subjected to
a small incision (~1 cm) in the thoracic region of each mouse
followed by suturing while a separate group was killed. After 12
more hours (24 h total post administration), the injured mice were
killed and Hct levels were measured and compared with
pre-treatment baseline values. As depicted in Figure 8, a
substantial decrease in Hct was observed in saline-treated KO
mice as compared with pre-treatment levels (17.9% (saline)
vs 47.7% (pre-treatment)). This decrease in Hct was inhibited
upon treatment with FIX MRT as a function of dose (36.1% and
39.0% for 0.25 and 0.50 mg kg− 1, respectively). Wild-type mice
were treated in an identical fashion with respect to both dose and
incision with no change in Hct levels observed. Such production of
active FIX protein after a single dose of FIX MRT demonstrates
therapeutic potential relevant for enabling treatment of severe
through mild classiﬁcations of hemophilia B patient population.
Summary
In summary, we have established successful encapsulation and
delivery of mRNA constructs to the liver using C12-200-based LNP
technology. Hepatocyte deposition and detection of active mRNA
was observed for two separate transcripts, hEPO and hFIX mRNA.
Furthermore, high level protein production (μg ml− 1) and
secretion sustained for up to 1 week post injection was achieved.
Active MRT-derived protein was conﬁrmed through pharmacody-
namic measures (increase in Hct (EPO)) and therapeutic means
(prevention of blood loss) in a hemophilia B (FIX KO) disease
model. These examples demonstrate the applicability of formu-
lated mRNA to treat not only organs of direct LNP uptake but also
sites within the body, which beneﬁt from the prolonged exposure
of MRT-derived protein secreted into the bloodstream.
MATERIALS AND METHODS
Lipid materials
The formulations described herein consisted of a multi-component lipid
mixture of speciﬁc ratios using a combination of lipidoid, helper lipids and
PEGylated lipids designed to encapsulate mRNA therapeutic molecules.
C12-200 was synthesized as previously described.61 DOPE (1,2-dioleyl-sn-
glycero-3-phosphoethanolamine, Avanti Polar Lipids, Alabaster, AL, USA)
and cholesterol (Sigma, St Louis, MO, USA) served as helper lipids within
the nanoparticle. The PEGylated lipid selected was a dimyristoyl glycerol–
polyethylene glycol (PEG) analog with a PEG molecular weight of
~ 2000 Da (DMG-PEG-2K) purchased from NOF (White Plains, NY, USA).
mRNA material
hEPO and hFIX were synthesized by in vitro transcription via T7 RNA
polymerase from a plasmid DNA template encoding the gene using
unmodiﬁed nucleotides, which was followed by the addition of a 5′-cap
structure (Cap 1) and a 3′-poly(A) tail of ~ 250 nucleotides in length as
determined by gel electrophoresis.80 Fixed 5′- and 3′-untranslated regions
were constructed to ﬂank the coding sequences of each mRNA. The
control mRNA consisted of a nonsense mutated coding sequence
designed to prevent protein production.
Formulation protocol
Example 1. Aliquots of 50 mg ml− 1 ethanolic solutions of C12-200,
DOPE, cholesterol and DMG-PEG2K were mixed and diluted with ethanol
to 3 ml ﬁnal volume. Separately, an aqueous buffered solution (10 mM
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citrate/150 mM NaCl, pH 4.5) of hEPO mRNA was prepared from a
1-mg ml− 1 stock. The lipid solution was injected rapidly into the aqueous
mRNA solution and shaken to yield a ﬁnal suspension in 20% ethanol. The
resulting nanoparticle suspension was ﬁltered, diaﬁltrated with 1 ×
phosphate-buffered saline (pH 7.4), concentrated and stored at
2–8 °C. Final concentration = 0.20 mg ml− 1 EPO mRNA (encapsulated).
% Encapsulation = 75%; % recovery = 81%; Zave = 91 nm (Dv(50) = 75 nm);
polydispersity = 0.14.
Example 2. Aliquots of 50 mg mL− 1 ethanolic solutions of C12-200, DOPE,
cholesterol and DMG-PEG2K were mixed and diluted with ethanol to 3 ml
ﬁnal volume. Separately, an aqueous buffered solution (10 mM citrate/
150 mM NaCl, pH 4.5) of hFIX mRNA was prepared from a 1-mg ml− 1 stock.
The lipid solution was injected rapidly into the aqueous mRNA solution
and shaken to yield a ﬁnal suspension in 20% ethanol. The resulting
nanoparticle suspension was ﬁltered, diaﬁltrated with 1 × phosphate-
buffered saline (pH 7.4), concentrated and stored at 2–8 °C. Final
concentration=0.20 mg ml−1 FIX mRNA (encapsulated). % Encapsulation
=78%; % recovery=79%; Zave =86 nm (Dv(50) = 69 nm); polydispersity=0.16.
In vivo animal models
EPO and FIX pharmacokinetic studies used 6- to 8-week-old male mice
(CD-1). For FIX efﬁcacy experiments, 10- to 12-week-old male mice (C57BL/
6J) were used as wild-type reference controls. Male FIX KO mice
(8–18 weeks old) were used for efﬁcacy studies.65 All mice were treated
via tail vein injection. Male cynomolgus monkeys (~4 kg) were treated with
a single intravenous injection as a total dose volume of 1 ml via ear vein
injection.
Select FIX KO mice were subjected to incision to determine efﬁcacious
treatment. At 12 h post dose administration, animals were anesthetized
with isoﬂurane before surgery. With the animals in a prone position, the
incision site (previously shaved) was aseptically prepared using betadine
followed by alcohol. The animals were subjected to a small (~1.0 cm)
surgical skin incision at the dorsal thoracic region and the incision was
closed with surgical sutures.
Analysis of protein produced via intravenously delivered mRNA-
loaded nanoparticles
Injection protocol. All pharmacokinetic studies were performed using
male CD-1 mice of ~ 6–8 weeks of age at the beginning of each
experiment. Samples were introduced by a single bolus tail vein injection
of the speciﬁed dose of encapsulated EPO or FIX mRNA-loaded LNPs. Mice
were killed and perfused with saline at the designated time points.
Isolation of organ tissues for analysis. The liver of each mouse was
collected and stored in either 10% neutral buffered formalin or snap-frozen
and stored at − 80 °C for analysis.
Isolation of plasma/serum for analysis. All animals were killed by CO2
asphyxiation at respective time points post administration (±5%) followed
by thoracotomy and terminal cardiac blood collection. Whole blood
(maximal obtainable volume) was collected via cardiac puncture on killed
animals. For serum collection, whole blood was placed into serum
separator tubes, allowed to clot at room temperature for at least 30 min,
centrifuged at 22± 5 °C at 9300 g for 10 min and extracted. For plasma
collection, whole blood was placed into either lithium heparin tubes or
citrate-coated tubes and processed to plasma. For interim blood
collections, ~ 40–50 μl of whole blood were collected via facial vein
puncture or tail snip. Samples collected from non-treatment animals were
used as a baseline level for comparison to study animals.
Enzyme-linked immunosorbent assay analysis. Quantiﬁcation of EPO
protein was performed following procedures reported for hEPO enzyme-
linked immunosorbent assay analysis kit (Quantikine IVD, R&D Systems,
Catalog # Dep-00; Minneapolis, MN, USA). Positive controls used consisted
of ultrapure and tissue culture grade recombinant hEPO protein (R&D
Systems, Catalog # 286-EP and 287-TC, respectively). Blood samples were
taken at designated time points and processed as described above.
Detection was monitored via absorption (450 nm) on a Molecular Devices
Flex Station instrument (Sunnyvale, CA, USA). Quantiﬁcation of FIX protein
was performed following procedures reported for hFIX ELISA kit
(AssayMax, Assay Pro, Catalog # EF1009-1; St Charles, MO, USA). High
speciﬁcity for the human forms of each respective protein was obtained
with no cross-reactivity observed in mouse samples (EPO/FIX) and minimal
cross-reactivity observed in monkey serum samples (EPO).
Hct analysis
Whole-blood samples were collected in heparinized micro-capillary blood
collection tubes and centrifuged at 10 000–15 000 g for 5 min at ambient
temperature. Packed cell volume was calculated vs total volume to obtain
Hct values.
FIX activity assay
FIX activity measurements in plasma samples were performed using the
Rossix Factor IX Activity Chromogenic Assay (ROX Factor IX 900020,
Mölndal, Sweden) according to the manufacturer’s instructions. Samples
were collected 12 h post dose administration.
hEPO and hFIX ISH assay
The detection of exogenous hEPO mRNA and hFIX mRNA was performed
by Advanced Cell Diagnostics (ACD, Hayward, CA, USA) using proprietary
technology involving a probe design strategy that allows simultaneous
signal ampliﬁcation and background suppression to achieve single-
molecule visualization while preserving tissue morphology. Tissues and
cells mounted on slides are ﬁrst pre-treated (antigen retrieval) to prepare
for hybridization. Oligonucleotide target probes (up to 20 probe pairs) are
hybridized to the RNA in the sample, followed by a series of steps and
washes designed to amplify the signal. The probe sets were designed to
not cross-react with mouse, rat, pig and rhesus monkey.
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